Quick Answer
ImmunityBio, Inc. reported Total Revenue of $113.29 million for fiscal year 2025.
ImmunityBio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $113.29M +668.3% |
$14.74M +2270.6% |
$622.0K +159.2% |
$240.0K -74.3% |
$934.0K +54.4% |
$605.0K -72.5% |
| Revenue (ASC 606) | $113.29M +668.3% |
$14.74M +2270.6% |
$622.0K +159.2% |
$240.0K | — | — |
| Net Income | -$351.40M +15.0% |
-$413.56M +29.1% |
-$583.20M -40.0% |
-$416.57M -20.1% |
-$346.79M -56.3% |
-$221.85M -40.6% |
| Diluted EPS | -$0.38 +38.7% |
-$0.62 +46.1% |
-$1.15 -10.6% |
-$1.04 -16.9% |
-$0.89 -50.8% |
-$0.59 -37.2% |
| Total Assets | $501.90M +31.1% |
$382.93M -24.1% |
$504.45M +39.2% |
$362.36M -22.7% |
$468.91M +111.8% |
$221.38M +54.7% |
| Cash and Equivalents | $88.33M -38.4% |
$143.43M -46.0% |
$265.45M +153.7% |
$104.64M -42.2% |
$181.10M +418.7% |
$34.91M -53.9% |
| Stockholders Equity | -$500.47M -2.3% |
-$489.10M +16.7% |
-$586.99M -31.2% |
-$447.33M -84.7% |
-$242.17M -102.1% |
-$119.81M -199.3% |
| R&D Expense | — | $190.14M -18.2% |
$232.37M -6.4% |
$248.15M +26.6% |
$195.96M +40.5% |
$139.51M +24.6% |
| Operating Income | -$256.03M +25.6% |
-$344.18M +5.0% |
-$362.25M -3.1% |
-$351.30M -6.4% |
-$330.28M -49.5% |
-$220.88M -41.4% |
| Shares Outstanding | 1.01B +18.6% |
852.90M +27.1% |
670.87M +59.1% |
421.57M +6.0% |
397.83M +4.1% |
382.24M +288.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $32.06M | +425.1% | +21.3% |
| Revenue (ASC 606) | September 30, 2025 | $32.06M | +425.1% | +21.3% |
| Net Income | September 30, 2025 | -$67.25M | +21.6% | +27.3% |
| Diluted EPS | September 30, 2025 | -$0.07 | +50.0% | +30.0% |
| Total Assets | September 30, 2025 | $518.99M | +42.4% | +29.1% |
| Cash and Equivalents | September 30, 2025 | $60.24M | -46.2% | -56.2% |
| Stockholders Equity | September 30, 2025 | -$524.32M | +29.6% | +8.1% |
| R&D Expense | September 30, 2024 | $50.44M | +4.2% | -1.3% |
| Operating Income | September 30, 2025 | -$55.63M | +30.7% | +22.0% |
| Shares Outstanding | September 30, 2025 | 984.97M | +41.3% | +7.6% |
- ImmunityBio, Inc. reported Total Revenue of $113.29 million for fiscal year 2025.
- ImmunityBio, Inc. showed an increase of +668.3% in Total Revenue compared to the prior fiscal year.
- ImmunityBio, Inc. reported Revenue (ASC 606) of $113.29 million for fiscal year 2025.
- ImmunityBio, Inc. showed an increase of +668.3% in Revenue (ASC 606) compared to the prior fiscal year.
- ImmunityBio, Inc. reported Net Income of -$351.40 million for fiscal year 2025.
- ImmunityBio, Inc. showed an increase of +15.0% in Net Income compared to the prior fiscal year.
- ImmunityBio, Inc. reported Diluted EPS of $0.38 per share (loss) for fiscal year 2025.
- ImmunityBio, Inc. showed an increase of +38.7% in Diluted EPS compared to the prior fiscal year.
- ImmunityBio, Inc. reported Total Assets of $501.90 million for fiscal year 2025.
- ImmunityBio, Inc. showed an increase of +31.1% in Total Assets compared to the prior fiscal year.
- ImmunityBio, Inc. reported Cash and Equivalents of $88.33 million for fiscal year 2025.
- ImmunityBio, Inc. showed a decrease of -38.4% in Cash and Equivalents compared to the prior fiscal year.
- ImmunityBio, Inc. reported Stockholders Equity of -$500.47 million for fiscal year 2025.
- ImmunityBio, Inc. showed a decrease of -2.3% in Stockholders Equity compared to the prior fiscal year.
- ImmunityBio, Inc. reported R&D Expense of $190.14 million for fiscal year 2024.
- ImmunityBio, Inc. showed a decrease of -18.2% in R&D Expense compared to the prior fiscal year.
- ImmunityBio, Inc. reported Operating Income of -$256.03 million for fiscal year 2025.
- ImmunityBio, Inc. showed an increase of +25.6% in Operating Income compared to the prior fiscal year.
- ImmunityBio, Inc. reported Shares Outstanding of 1.01 billion shares for fiscal year 2025.
- ImmunityBio, Inc. showed an increase of +18.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: